Primary progressive multiple sclerosis is associated with neurodegeneration and chronic inflammation, and results in the accumulation of gradual disability. This pilot study investigated 92 plasma proteins using proximal extension assay to identify MS subtype-specific biomarkers with a focus on predicting primary progressive MS. We analyzed samples from 66 MS patients (22 relapsing-remitting, 22 secondary progressive, and 22 primary progressive) and 22 controls. ANOVA identified five proteins (ACAN, TMSB10, BST1, CLEC11A, MYOC) with p < 0.05 for differentiating phenotypes of MS, four of which have been previously implicated in MS pathophysiology. However, after correcting for multiple comparisons no individual proteins remained statistically significant. Logistic regression and support vector models using these 5 proteins for predicting primary progressive, in one-vs all-models, against other MS phenotypes and controls were of low accuracy (0.69 and 0.68, respectively). While not immediately translatable, these results lay the groundwork for future studies into MS progression biomarkers.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Duke University Institutional IRB exemption was obtained (Pro00112531).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes